FORE!!!!! We need golfers and hole sponsors!!! With just a little over two weeks to go, Rein in Sarcoma will be hosting a charity golf event Friday August 25th at the beautiful Deer Run Golf Club in Victoria, MN. This event will benefit Rein in Sarcoma’s mission of Education, Patient & Family Support, and Research to improve treatment and find a cures for sarcoma cancers.
So clean up your clubs and put together your team of four, or sign up individually (we will help put you in a foursome). We'll play a scramble format on a beautiful course for a great cause. Lunch and steak dinner are included, as well as games on the course and an Under Armour® sports bag player gift.
For more information about registration and sponsorship opportunities visit the RIS Golf Challenge page or call Paul Giel Jr. at 612-618-4841.
RIS is a volunteer rich organization and we’re adding a regular feature to highlight the contributions made by one of our many fantastic volunteers.
Prior to joining the Public Relations and Marketing team in 2015 and befriending sarcoma survivors, Valeria López had no connection to sarcoma cancer. She has become an invaluable leader on our very active PR/Marketing Committee, using her graphic design, photography and videography skills to help us completely re-brand the organization, distribute comprehensive and visually appealing annual reports, design raffle tickets, gorgeous graphics and posters for RIS events, and record powerful sarcoma survivor stories.
This year, in addition to the Party in the Park and Fall Fundraiser graphics, Val worked with her Graphic Design students at Century College to re-design the Rein in Sarcoma organizational brochure. It was a great opportunity for the students to both learn about RIS and try out their newly learned design skills. The PR and Marketing committee chose the best brochure and the student was given an honorable mention at the Party. We hope you were able to pick up one of the brochures at the Picnic or Party.
We are SO thankful for Val’s time, talent and dedication to our organization. We would love to have YOU join us as a volunteer. Learn more about volunteering with RIS.
“Deeper understanding of disease biology may expand sarcoma treatment options” - HemOnc Today, July 10, 2017
That’s the title of a good up-to-date review of sarcoma. There are over 50 major types of sarcoma. Some of these sarcoma types don’t have many subtypes, an example is synovial sarcoma, and some have many, for example osteosarcoma. Researchers found over 60,000 mutations when checking the DNA in 107 patients. Most of these mutations don’t have a role in cancer, some are just a part of growing up. Sixty of the 107 patients had mutations that could be treated, what these researchers called actionable. Most of the treatments are not cure, or disappearance of the tumor, just slowing of growth.
Ewing’s sarcoma has a translocation in the chromosomes. That is relatively easy to find, yet treatment for this “obvious” abnormality has so far proven disappointing. Many sarcomas don’t have readily findable markers in testing the DNA, making it a challenge to treat some of these cancers.
Dr. Brenda Weigel of the U of Minnesota commented that treating these cancers when they recur is especially difficult. She stated; “Over the last decade we have gained a much greater understanding of some of the biology that is relevant to different types of sarcomas, but it has also shown us that we know very little.” Olaratumab is a new drug that has shown some help in phase two studies, and that is encouraging, the first drug to show benefit in osteosarcoma in the advanced disease situation. The contemplated phase 3 study will evaluate the drug in a larger population. Not yet ready for general use.
Erybulin mesylate was approved by the FDA in 2016 and is the first drug to show benefit in liposarcoma. In 2015 Yondelis (trabectidin) was approved and was the first approved treatment for liposarcoma and leiomyosarcoma in 30 years!
So much research is being done into the biology of cancer, and also sarcoma, worldwide. Examining the deep abnormalities in the genetics of cancer has opened new doors and stimulated the work toward new drugs. It is hopeful.
Larry Seymour, MD
RIS Board Member
Link to the referenced article in HemOnc Today, July 10, 2017